NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class (Descending) | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
73358-0210-16 | 73358-0210 | Docetaxel Anhydrous | Docetaxel Anhydrous | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct. 17, 2022 | In Use | |
00024-5824-11 | 00024-5824 | Cabazitaxel | Jevtana | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | June 17, 2010 | In Use | ||
00143-9204-01 | 00143-9204 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan. 14, 2021 | In Use | |
00143-9205-01 | 00143-9205 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan. 14, 2021 | In Use | |
00955-1020-01 | 00955-1020 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct. 21, 2010 | In Use | |
00955-1021-04 | 00955-1021 | Docetaxel | Docetaxel | 80.0 mg/4mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct. 21, 2010 | In Use | |
00955-1022-08 | 00955-1022 | Docetaxel | Docetaxel | 160.0 mg/8mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct. 23, 2016 | In Use | |
61703-0342-09 | 61703-0342 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | March 1, 2004 | In Use | |
61703-0342-22 | 61703-0342 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | March 1, 2004 | In Use | |
61703-0342-50 | 61703-0342 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | March 1, 2004 | In Use | |
00517-4300-01 | 00517-4300 | Paclitaxel | PACLITAXEL PROTEIN BOUND PARTICLES ALBUMIN BOUND | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | May 2, 2023 | In Use | |
70860-0200-05 | 70860-0200 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | March 24, 2017 | Dec. 31, 2024 | In Use |
70860-0200-17 | 70860-0200 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | March 24, 2017 | Nov. 30, 2024 | In Use |
70860-0200-50 | 70860-0200 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | March 24, 2017 | Dec. 31, 2024 | In Use |
70860-0215-66 | 70860-0215 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Dec. 15, 2021 | Sept. 30, 2024 | In Use |
70860-0215-67 | 70860-0215 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Dec. 15, 2021 | Nov. 30, 2024 | In Use |
70860-0215-68 | 70860-0215 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Nov. 30, 2019 | April 30, 2024 | In Use |
25021-0255-05 | 25021-0255 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb. 1, 2024 | In Use | |
25021-0255-17 | 25021-0255 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb. 1, 2024 | In Use | |
25021-0255-50 | 25021-0255 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb. 1, 2024 | In Use | |
50242-0091-30 | 50242-0091 | ENTRECTINIB | Rozlytrek | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | TRKA, TRKB, TRKC, ROS1, ALK | Oral | Aug. 15, 2019 | In Use | |
50242-0091-86 | 50242-0091 | ENTRECTINIB | Rozlytrek | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | TRKA, TRKB, TRKC, ROS1, ALK | Oral | Aug. 15, 2019 | In Use | |
50242-0092-01 | 50242-0092 | ENTRECTINIB | Rozlytrek | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | TRKA, TRKB, TRKC, ROS1, ALK | Oral | Aug. 15, 2019 | No Longer Used | |
50242-0092-86 | 50242-0092 | ENTRECTINIB | Rozlytrek | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | TRKA, TRKB, TRKC, ROS1, ALK | Oral | Aug. 15, 2019 | No Longer Used | |
50242-0094-47 | 50242-0094 | ENTRECTINIB | Rozlytrek | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | TRKA, TRKB, TRKC, ROS1, ALK | Oral | Aug. 15, 2019 | In Use |
Found 10,000 results in 4 milliseconds — Export these results